colonies with an undifferentiated or blast-like morphology (Fig.1F ). Taken together, these experiments, using Bmi1 constitutive or conditional knockout-mice, revealed that Bmi1 is critical for the initiation as well as maintenance of transformation by the CALM-AF10 fusion oncogene.
Small-molecule BMI1 inhibition impairs murine CALM-AF10 AML growth and survival
Recently, small molecule inhibitors of BMI1 have been developed (Kreso et al., 2014; Nishida et al., 2017) . We wanted to investigate whether these BMI1 inhibitors are active against CALM-AF10-driven AML. In order to do so, we utilized PTC-209, a novel small molecule inhibitor of BMI1, previously used to target colorectal cancer, chronic leukemia and multiple myeloma (Mayr, Neureiter, Wagner, Pichler, & Kiesslich, 2015; Mourgues et al., 2015) . been reported to reduce expression of BMI1 protein by altering regulation of the translation of the BMI1 mRNA (Kreso et al., 2014) . We examined the effect of PTC-209 on mouse CALM-AF10 AML cell-growth by treating primary AML cells from three independently derived tumors. Cells were exposed to varying concentrations of PTC-209 for up to six days together with DMSO treated controls, and viable-cell counting performed every two days. First, we confirmed on-target activity of PTC-209 by ensuring the derepression of the Cdkn1a locus, a well characterized tumor suppressor locus that is transcriptionally repressed by Bmi1 activity (Fig. S2A ). We then assessed the effect of PTC209 on CALM-AF10-transformed AML cells in proliferation assays in vitro. We observed that PTC209 induced a highly significant and concentration-dependent decrease in the number of viable CALM-AF10 AML cells over time ( Fig. 2A ) in comparison to their vehicle-treated counterparts. This decrease in cell viability was accompanied by a significant increase in AnnexinV positive cells, demonstrating induction of apoptosis upon PTC-209 treatment (Fig. 2B ). The sensitivity of CALM-AF10 AML cells to PTC-209 was in the nanomolar range with an EC50 of 500nM.
Furthermore, compared to vehicle-treated AML cells, PTC-209 treatment also significantly reduced the clonogenic capacity of CALM-AF10 cells in CFU-assays in a concentrationdependent manner ( Fig. 2C and 2D ). These results demonstrate that small-molecule BMI1 inhibitor significantly inhibits the proliferative activity as well as clonogenic capability of murine CALM-AF10 AML cells.
Pharmacological BMI1 inhibition impairs human CALM-AF10 AML in vitro and in vivo
We wanted to confirm our findings from the mouse models in human CALM-AF10-rearranged AML. For this, we treated the CALM-AF10-rearranged AML cell lines U937, KPMOTS and P31/Fujioka in vitro with DMSO or PTC209 at various concentrations, and assessed the effect on proliferation, cell cycle and apoptosis. In proliferation assays, we observed a significant and concentration-dependent decrease in viable cell counts of all three cell lines upon treatment with PTC209, compared to DMSO controls (Fig. 3A) . PTC-209 also induced consistent increases in Annexin V positive cell populations compared to the vehicle, with the most significant and most pronounced difference in P31/Fujioka cells ( Fig. 3B ). Similar to mouse CALM-AF10transformed cells, BrdU incorporation analysis showed an increase in the proportion of G0/G1 phase cells in U937, P31/Fujioka and KPMOTS cell lines, with a corresponding decrease in Sphase cells ( Fig. 3C ). Taken together, small-molecule BMI1 inhibition results in cell-cycle arrest features that are coupled with increased cell death and reduced proliferation of CALM-AF10driven human AML cell lines, in concordance WITH our mouse model data.
Next, we wanted to validate our findings in vivo. For this, we used PTC596, a compound in clinical development identified by its ability to inhibit proliferation of BMI1 positive cancer stem cells (reference). The mechanism of BMI1 protein reduction is thought to be due to G2/M arrest causing accelerated ubiquitination and degradation of the BMI1 protein (reference). We assessed the ability of PTC596 to inhibit CALM-AF10-driven in vivo leukemogenesis. First, we injected immunodeficient mice (NRG-SGM3) with the P31/Fujioka cell line. Ten days after injection, we confirmed engraftment of P31 cells in mice by flow-cytometric assessment of the human CD45 marker (data not shown). We then orally administered one cohort of mice with PTC-596 and an age and engraftment matched cohort was administered the vehicle control. We observed that PTC596-treatment significantly delayed the latency of disease in mice compared to controls ( Fig.   4 ) demonstrating the in vivo efficacy of small-molecule BMI targeting in this setting.
In summary, our results demonstrate that BMI1 is a bonafide candidate for therapeutic targeting in AML with CALM-AF10 rearrangements and possibly other leukemias with CALM-AF10 rearrangements.
MATERIALS AND METHODS

Reagents
PTC-209 was obtained from Cayman Chemical Co. (Ann Arbor, MI, USA), dissolved in DMSO and stored at -80 °C. PTC596 and its vehicle solution for in vivo studies were provided by PTC Therapeutics (South Plainfield, NJ, USA).
Animal experiments
Bmi1-green fluorescent protein (GFP) transgenic mice (BKa.Cg-Ptprc b Bmi1 tm1Ilw Thy1 a /J) mice were obtained from The Jackson Laboratories (Bar Harbor, ME, USA, JAX # 017351) and maintained in the SBP animal facility. Bmi1 fl/fl (Mich et al., 2014) mice were obtained from the Jackson Laboratories (JAX #028974). All experiments using mice were conducted as per procedures approved by the SBP Institutional Animal Ethics Committee.
Cell culture
The human acute myeloid leukemia (AML) cell line U937 was a kind gift of Daniel Tenen, Beth Israel Deaconess Medical Center. The P31/Fujioka cells were obtained from the JCRB cell bank (#JCRB0091). KP-MO-TS was a kind gift from Dr. Issay Kitabayashi, National Cancer Center, Tokyo. All cell lines were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine (Gibco) and 100 U/ml penicillin/streptomycin (Gibco).
Murine bone marrow cells from the femur and tibia were depleted of lineage positive cells using the EasySep™ Mouse Hematopoietic Progenitor Cell Isolation Kit (#19856, StemCell Techologies, Vancouver, Canada) and cultured overnight in DMEM (Gibco) media supplemented with 15% FBS (Gibco), 2 mM L-glutamine (Gibco), 100 U/ml penicillin/streptomycin (Gibco)and a cytokine cocktail containing mIL3, mIL6 and mSCF (Peprotech Inc). The following day, the cells were transduced with a retrovirally encoded version of CALM-AF10 bearing the C-terminal clathrin-binding domain of CALM and the octapeptide motif-leucine-zipper of AF10, as described in A J Deshpande et al., 2011. These BM progenitors transduced with the CALM-AF10 fusion were then either used directly for experiments or injected into mice.
In vivo drug experiment
The xenograft model was established with NRG/SRM3 mice obtained from the SBP Animal Facility. Mice were irradiated (2.5 Gy) and 2x10 5 P31/Fujioka cells were then injected intravenously. At 9 days post-injection, mice were randomized into two groups (n=5) to receive either PTC596 (12.5 mg/kg) or vehicle (0.5% hydroxypropyl methylcellulose and 0.1% Tween 80 in distilled water) by oral gavage twice per week. Circulating leukemia cells were detected on day 8 by flow cytometry using a human-specific CD45 antibody (#404012, Biolegend, San Diego). Mice were sacrificed upon signs of morbidity.
Embryo generation and isolation of fetal liver cells
Embryos were generated from timed matings between male and female BKa.Cg-Ptprcb Bmi1tm1Ilw Thy1a/J mice. Detection of the vaginal plug was designated as E0.5. Pregnant females were sacrificed by cervical dislocation at E14.5. The uterine horns were removed and fetuses were separated from maternal tissue. Fetal livers were dissected, and single cell suspensions were obtained by straining tissues through a 10-micron mesh. Red blood cell (RBC) lysis was performed using 1X RBC Lysis Buffer (Sigma-Aldrich) according to the manufacturer's guidelines. Fetal liver cells were cultured in DMEM (Gibco, Grand Island, NY) media containing 15% FBS, 2 mM L-glutamine (Gibco, Grand Island, NY), 100 U/ml penicillin/streptomycin (Gibco, Grand Island, NY) and a cytokine cocktail (mIL6, mIL3 and mSCF from Peprotech Inc, Rocky Hill, USA, #216-16, #213-13, #250-03).
Cell proliferation assays
Mouse and human (U937, P31-Fujioka and KP-MO-TS) CALM-AF10 cell lines were seeded and treated with DMSO (control) or PTC-209 (1 μM or 5 μM). Samples were taken on the second, fourth and sixth day after setup of the assay. Cell viability on treatment of PTC-209 was determined by using Sytox Blue Dead Cell Stain (Invitrogen) via flow cytometry. Analysis was performed on an LSR Fortessa (BD Biosciences).
Cell cycle and apoptosis assay
Apoptosis induction was determined by combined Annexin V and Sytox staining. CALM-AF10 cell lines were treated with either DMSO or PTC-209 at 2.5 μM. After 48h, cells were harvested and stained with Annexin V-APC (#550474, BD Pharmingen) for 15 minutes on ice in the dark.
The cells were washed and stained with and Sytox Blue Dead Cell Stain (Invitrogen, Thermo Fisher Scientific) before performing analysis. Cell cycle assessment was performed after 20 min of labeling with a BrdU-APC Flow kit (#552598, BD Pharmingen), following the manufacturer's guidelines. All flow cytometric analyses were performed on an LSR Fortessa (BD Biosciences).
Colony formation assay
Mouse CALM-AF10 cell lines either treated or untreated with PTC-209 at 1 μM or 2.5 μM were plated in duplicates in 1.1 ml methylcellulose-based medium (MethoCult 3234, StemCell Techologies, Vancouver, Canada) per well, containing 460 pM mIL6, 1090 pM mSCF and 662 pM mIL3 (Peprotech Inc) and incubated for 7 days. At the end of the incubation period, the number of blast and differentiated colonies was scored using an inverted microscope.
Quantitative RT-PCR
Total RNA was isolated using TRIzol (#15596026, Thermo Fisher Scientific, San Jose, CA, USA) according to the manufacturer's instructions. cDNA was synthesized from extracted RNA using the ProtoScript First Strand cDNA Synthesis Kit (#E6300, New England Biolabs Inc, Beverly, MA, USA). CDKN1A expression levels were measured using quantitative PCR (qPCR) using TaqMan Universal PCR Master Mix and pre-designed TaqMan gene expression assays (Applied Biosystems, Foster City, CA, USA) on the Stratagene MX3000P (Agilent Technologies, La Jolla, CA, USA).
Statistical Analysis
Flow cytometry data was analyzed using FlowJo (FlowJo Software, Tree Star, Ashland, OR). All statistical analyses were performed using GraphPad Prism 7 Software (San Diego, CA, USA), except for violin plots and analysis from Figure S1for which the R Statistical Software was used. P values were calculated using the Student's t-test.
DISCUSSION
Despite the well-described oncogenic activity of BMI1 in a wide range of human cancers, therapeutic BMI1 targeting has proven to be elusive. Recently, the BMI1 small-molecule inhibitor PTC209 was developed by PTC Therapeutics (Kreso et al., 2014) and has been used in preclinical studies to treat chronic and acute myeloid leukemia (Mourgues et al., 2015) , biliary tract cancer (Mayr et al., 2015) , multiple myeloma (Bolomsky et al., 2017; Bolomsky, Schlangen, Schreiner, Zojer, & Ludwig, 2016) , non-small cell lung cancer (Yong et al., 2016) , glioblastoma (Jin et al., 2017) , ovarian cancer (Dey et al., 2016) , prostate cancer (Bansal et al., 2016) , breast cancer (Dimri et al., 2016) and colorectal cancer (Kreso et al., 2014) . Furthermore, a next-generation clinical-grade BMI1 inhibitor PTC596 has been developed, which is currently in clinical trials for advanced solid tumors (Infante et al., 2017) . The fact that elevated BMI1 expression is a common feature of CALM-AF10 leukemias regardless of lineage suggests that BMI1 may be a transcriptional target of the CALM-AF10 fusion protein. Intriguingly, we have previously noted that BMI1 is located on chromosome 10 adjacent and downstream of the wildtype AF10 gene (M. A. Mulaw et al., 2012) . Therefore, it is also likely that the CALM-AF10 fusion-event drives enhanced BMI1 expression through the disruption of topologically associated domains (TADs) and juxtaposition of BMI1 to the strong, CALM-associated enhancers, as a result of the t(10;11) translocation. Since elevated Bmi1 expression can be observed even in mouse models of CALM-AF10-driven AML (M. A. Mulaw et al., 2012) which do not harbor a t(10;11) translocation, the former scenario is more likely, although the latter possibility with TAD activation cannot completely be ruled out. Regardless of the mechanism of BMI1 activation, this characteristic CALM-AF10-associated molecular event may create a novel dependency that is therapeutically tractable.
The role of BMI1 in AML has been studied in the context of leukemias driven by other leukemia-associated oncogenes. Interestingly, genetic experiments demonstrate that the dependency on BMI1 is selective. Bmi1 was first reported to be important for AML stem cells in a murine study using a retroviral model of Hoxa9 and Meis1 co-expression (Lessard & Sauvageau, 2003) . This study showed that Bmi1 deletion does not affect the initiation of Hoxa9-Meis1-driven AML, but significantly impairs the ability of primary leukemias to transmit disease in secondary recipients (Lessard & Sauvageau, 2003) . This study indicated that Bmi1 was important for the self-renewal of leukemia stem cells in the retroviral Hoxa9-Meis1 coexpression model. Other studies demonstrated that while myeloid transformation driven by the fusion oncoproteins AML1-ETO and PLZF-RARA is strongly sensitive to Bmi1 depletion (Boukarabila et al., 2009; Smith et al., 2011) , leukemias driven by the MLL-AF9 fusion oncoprotein are not dependent on Bmi1 expression (Smith et al., 2011) . Another study with the MLL-AF9 fusion protein observed that Bmi1 was necessary for the generation of AML from granulocyte macrophage progenitors (GMPs), indicating that BMI1 may be critical for leukemic transformation of downstream hematopoietic progenitors by MLL-AF9, but not for the transformation of hematopoietic stem cells (HSCs) (Yuan et al., 2011) . These studies demonstrate the selective requirement of BMI1 depending on the mutational sub-type of AML as well as on the developmental stage of the leukemia cells. In our studies, CALM-AF10-driven transformation seems to require Bmi1 both for the initiation of transformation as well as maintenance. More recently, the small-molecule BMI1 inhibitors PTC209 as well as PTC596
have been used to demonstrate that a broad panel of human AML cell lines are sensitive to small-molecule BMI1 inhibition (Mourgues et al., 2015; Nishida et al., 2015 Nishida et al., , 2017 although none of these studies focused specifically on CALM-AF10-rearranged AML. In CALM-AF10, the clinical rationale for BMI1 targeting may be clearer, given that BMI1 is strongly upregulated in CALM-AF10 rearranged AML.
Our observation that CALM-AF10 fusions require BMI1 for initiation as well as maintenance of transformation provides pre-clinical evidence that pharmacological BMI1 inhibition may provide potential clinical benefit in leukemias with CALM-AF10 rearrangements. These results could help inform future clinical trials with BMI1 inhibitors. It is pertinent to note that BMI1 upregulation is observed not only in CALM-AF10 positive AML, but also in T-ALL, where elevated BMI1 expression was first noted (Dik et al., 2005b) . It is therefore very likely that small-molecule BMI1 inhibition is a lineage-independent vulnerability associated with CALM-AF10-rearrangements. The hypothesis that CALM-AF10-rearranged T-ALLs may also be sensitive to BMI1 inhibition needs to be validated using T-ALL models of this disease. Even though CALM-AF10 fusions are more frequent in T-ALL than in AML, CALM-AF10 mouse models reported so far are biased towards the myeloid lineage (David Caudell, Zhang, Yang, & Aplan, 2007; A. J. Deshpande et al., 2011; Aniruddha J. Deshpande et al., 2006; Dutta et al., 2016) , hampering the validation of therapeutic candidates for CALM-AF10 positive T-ALL.
Future studies will focus on the development of CALM-AF10 T-ALL models and the validation of BMI1 inhibitors in these studies.
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